Navigation Links
Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/13/2009

ared to $82,000 for the quarter ended March 31, 2008.

Merger-related transaction costs of approximately $2.2 million were expensed during the quarter ended March 31, 2009.

Net loss attributable to common stockholders in the quarter ended March 31, 2009 was $8.5 million or $0.95 per share, compared to a net loss of $5.1 million or $14.11 per share for the quarter ended March 31, 2008. The weighted average common shares used to calculate earnings per share were 9,003,067 and 359,602 respectively for the quarters ended March 31, 2009 and 2008. At March 31, 2009 there were 13,064,398 common shares outstanding and 2,228,061 outstanding options, warrants and common stock subject to repurchase.

After giving effect to the merger of Transcept and Novacea, the combined cash, cash equivalents and marketable securities of the company on January 30, 2009 was estimated to be approximately $92 million. Subsequent to the close of the merger, and during the first quarter of 2009, Transcept paid non-recurring merger related expenses including financial advisory fees of $2.0 million and legal fees, audit fees, consulting fees and financial printing costs totaling approximately $1.1 million. In February 2009, Transcept also retired all principal and interest owed to Hercules Technology Growth Capital in the amount of $3.4 million. Cash, cash equivalents and marketable securities totaled $81.0 million at March 31, 2009.

2009 Guidance

Transcept continues to expect full year 2009 research and development expenses to remain consistent with 2008 levels until such time as Transcept initiates development of pipeline product candidates or any post approval clinical development activities of Intermezzo(R). Full year 2009 general and administrative expenses are expected to increase as compared to 2008 as Transcept has increased its administrative infrastructure to comply with the requirements of bei
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
2. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
3. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
4. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
5. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
6. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
7. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 As kinship ... for children who cannot live with their parents, emphasis ... to continue to enhance services and supports for kinship ... America’s (CWLA) National Kinship Care Conference is being held ... knowledge of best practice, policy, program and service development ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... July 1 AlphaMed Press, co-publisher of the journal ... stem cells and regenerative medicine, has promoted Miodrag Stojkovic ... is Deputy Director of the Prince Felipe Research Centre ... Spain. He led the team that first announced derivation ...
... ... two winners of their 2009 North American Grant Program. Exiqon had recently announced ... non-profit institutions across North America, engaged in microRNA research. , ... (PRWEB) July 1, 2009 -- Exiqon A/S ...
... ... the past 30 years, The Free Choice Foundation is a newly established grassroots organization ... with regards to healthcare. , ... Tokyo, Japan (PRWEB) July 1, 2009 -- Based on the spirit of ...
... Also recommends dosing limits for OTC products that contain ... liver damage. , TUESDAY, June 30 (HealthDay News) ... combine acetaminophen with an opiate narcotic, should be banned, ... like Tylenol or Excedrin, should be lowered, a U.S. ...
... Disease , , WASHINGTON, June 30 Today Lung ... Cancer illustrating again the devastating toll caused by lung cancer. ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) ... analyzes the most recent available data from the National Institutes of ...
... Andrew Ordon, co-host of the syndicated talk show The ... a non-invasive skin contouring procedure, at his state-of-the-art surgical facilities ... is the perfect option for someone who wants to look ... explains Ordon. "There is little to no downtime with this ...
Cached Medicine News:Health News:STEM CELLS Promotes Miodrag Stojkovic to Editor 2Health News:Exiqon Announces 2009 North American Grant Award Winners 2Health News:Exiqon Announces 2009 North American Grant Award Winners 3Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 2Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 2Health News:FDA Panel Urges Ban on Vicodin, Percocet 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 4Health News:Lung Cancer Alliance Releases Updated 2009 Facts About Lung Cancer 2
(Date:9/17/2014)... TAMPA, Fla. , Sept. 17, 2014   ... announced today that Business Insurance magazine has ... Insurance" distinction for the third year in a row. ... joint effort of Business Insurance  and the Best ... evaluation, is open to all publicly or privately-held insurance ...
(Date:9/17/2014)... ANGELES and LEIPZIG, Germany ... today announced that it has entered into an ... the development of antibody-based imaging agents to image ... "Our collaboration with Novotectid expands ImaginAb,s capability to precisely ... immune-oncology and autoimmune disease areas. The ability to ...
(Date:9/17/2014)... PALO ALTO, Calif. , Sept. 17, 2014 /PRNewswire/ ... of the Company,s Phase 2 clinical program of NP001 ... Lou Gehrig,s disease) are being highlighted today ... of the ALS Research Group , being held in ... According to a  post hoc  analysis, administration of a ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... Reportlinker.com announces that a new market research report ... Drug Delivery in Central Nervous System Diseases - ... The delivery of drugs ... in the treatment of neurological disorders. Drugs may ...
... Robbins & Myers, Inc. (NYSE: ... its Romaco businesses to a group of funds led ... investment firm.  Total consideration was approximately euro 65 million ... and euro 4 million of assumed liabilities and is ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 4
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
50L...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Medicine Products: